Cumberland Pharmaceuticals Files 8-K Report

Ticker: CPIX · Form: 8-K · Filed: Feb 19, 2025 · CIK: 1087294

Sentiment: neutral

Topics: regulatory-filing, 8-K

Related Tickers: CPRX

TL;DR

CPRX filed an 8-K on Feb 19, 2025. Details TBD.

AI Summary

On February 19, 2025, Cumberland Pharmaceuticals Inc. filed an 8-K report. The filing primarily concerns "Other Events" and does not detail specific transactions or financial figures within the provided text. The report confirms the company's identity, its state of incorporation (Tennessee), and its principal executive offices located in Nashville, TN.

Why It Matters

This filing indicates a regulatory update from Cumberland Pharmaceuticals Inc., requiring investors and interested parties to review the full document for any material information disclosed.

Risk Assessment

Risk Level: low — The provided text is a standard 8-K filing notification without specific financial or operational disclosures that would indicate immediate risk.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The filing is categorized under "Other Events" and serves as a current report filed by Cumberland Pharmaceuticals Inc. pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.

When was this 8-K report filed?

The report was filed on February 19, 2025.

What is the exact name of the registrant?

The exact name of the registrant is CUMBERLAND PHARMACEUTICALS INC.

In which state is Cumberland Pharmaceuticals Inc. incorporated?

Cumberland Pharmaceuticals Inc. is incorporated in Tennessee.

Where are the principal executive offices of Cumberland Pharmaceuticals Inc. located?

The principal executive offices are located at 1600 West End Avenue, Suite 1300, Nashville, Tennessee 37203.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on February 19, 2025 regarding CUMBERLAND PHARMACEUTICALS INC (CPIX).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing